Evidence map›Paper›PMID 37839102›Full record

ArticleThe Journal of surgical research2024

Humanized Anti-Carcinoembryonic Antigen Antibodies Brightly Target and Label Gastric Cancer in Orthotopic Mouse Models.

Kristin E Cox, Michael A Turner, Siamak Amirfakhri, Thinzar M Lwin, Mojgan Hosseini, Pradipta Ghosh, Marygorret Obonyo, Takashi Murakami, Robert M Hoffman, Paul J Yazaki and 1 more

Open access · greenAbstract read
In one paragraph

Article in The Journal of surgical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Kristin E CoxDepartment of Surgery, University of California San Diego, La Jolla, California; Department of Surgery, VA San Diego Healthcare System, La Jolla, California.
Michael A TurnerDepartment of Surgery, University of California San Diego, La Jolla, California; Department of Surgery, VA San Diego Healthcare System, La Jolla, California.
Siamak AmirfakhriDepartment of Surgery, University of California San Diego, La Jolla, California; Department of Surgery, VA San Diego Healthcare System, La Jolla, California.
Thinzar M LwinDepartment of Surgical Oncology, City of Hope National Medical Center, Duarte, California.
Mojgan HosseiniDepartment of Pathology, University of California San Diego, La Jolla, California.
Pradipta GhoshDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California; Department of Medicine, University of California San Diego, La Jolla, California.
Marygorret ObonyoDepartment of Medicine, University of California San Diego, La Jolla, California.
Takashi MurakamiDepartment of Microbiology, Saitama Medical University, Saitama, Japan.
Robert M HoffmanDepartment of Surgery, University of California San Diego, La Jolla, California; Department of Surgery, VA San Diego Healthcare System, La Jolla, California; AntiCancer Inc, San Diego, California.
Paul J YazakiDepartment of Immunology & Theranostics, Beckman Research Institute of the City of Hope, Duarte, California.
Michael BouvetDepartment of Surgery, University of California San Diego, La Jolla, California; Department of Surgery, VA San Diego Healthcare System, La Jolla, California. Electronic address: mbouvet@ucsd.edu.
University of California San Diego · USCity Of Hope National Medical Center · USSaitama Medical University · JP

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jesse Nodora · 1985 to 2026
$124.9M
UCSD Cancer Center Training Program in Drug DevelopmentT32CA121938 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Bouvet, Dwayne G. Stupack · 2006 to 2026
$10.3M
Spatial Regulation of RGS and G Protein SignalingR01CA100768 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA · 2003 to 2019
$7.4M
UC San Diego RAPID Faculty Development Program in Infectious DiseasesR25AI147376 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ADRIANA H TREMOULET, Joann Trejo · 2020 to 2026
$2.5M
Integrators of Metastatic PotentialR01CA238042 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA, LUKER, GARY D · 2019 to 2023
$2.3M
Molecular Imaging Probe(s) for Optical Surgical Navigation of Pancreatic CancerR01CA256973 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Surinder K. Batra, Michael Bouvet · 2022 to 2026
$2.2M
Fluorophore-Conjugated Antibodies for Imaging and Resection of GI TumorsR01CA142669 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BOUVET, MICHAEL, YANG, MENG · 2010 to 2015
$1.7M
Network-Based Novel Therapeutics in Colorectal CancersUG3TR002968 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DAS, SOUMITA, GHOSH, PRADIPTA · 2019 to 2021
$946k
Network-Based Novel Therapeutics in Colorectal CancersUH3TR002968 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DAS, SOUMITA, GHOSH, PRADIPTA · 2022 to 2022
$356k
CMA- Marker-assisted prevention and risk stratification (MAPRS): Mucin signatures and molecular imaging for the early detection of colorectal cancer.I01BX004494 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI BOUVET, MICHAEL · 2020 to 2023
–
Development of Near Infrared Fluorescence-Guided Surgical Navigation and Tumor Specific Photoimmunotherapy for Improved Outcomes for GI CancersI01BX003856 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI BOUVET, MICHAEL · 2018 to 2022
–
BLRD VA I01 BX003856BLRD VA I01 BX004494NCATS NIH HHS UG3 TR002968NCATS NIH HHS UH3 TR002968NCI NIH HHS P30 CA023100NCI NIH HHS R01 CA100768NCI NIH HHS R01 CA142669NCI NIH HHS R01 CA238042NCI NIH HHS R01 CA256973NCI NIH HHS T32 CA121938NIAID NIH HHS R25 AI147376
6 · The paper itself

Abstract

introductionGastric cancer poses a major therapeutic challenge. Improved visualization of tumor margins at the time of gastrectomy with fluorescent tumor-specific antibodies could improve outcomes. The present report demonstrates the potential of targeting gastric cancer with a humanized anti-carcinoembryonic antigen (CEA) antibody in orthotopic mouse models.

methodsMKN45 cells were injected subcutaneously into nude mice to establish xenograft models. Tumor fragments collected from subcutaneous models were then implanted into the greater curvature of the stomach to establish orthotopic models. For tumor labeling, a humanized anti-CEA antibody (M5A) and IgG as a control, were conjugated with the near-infrared dye IRDye800CW. Time (24-72 h) and dose (50-100 μg) response curves were performed in subcutaneous models. Orthotopic models received 50 μg of M5A-IR800 or 50 μg IgG-IR800 as a control and were imaged after 72 h. Fluorescence imaging was performed on the mice using the LI-COR Pearl Imaging System.

resultsIn subcutaneous models, tumor to background ratios (TBRs) reached 8.85 at 72 h. Median TBRs of orthotopic model primary tumors were 6.25 (interquartile range [IQR] 6.03-7.12) for M5A-IR800 compared to 0.42 (IQR 0.38-0.54) for control. Abdominal wall metastasis median TBRs were 13.52 (IQR 12.79-13.76) for M5A-IR800 and 3.19 (IQR 2.65-3.73) for the control. Immunohistochemistry confirmed CEA expression within tumors.

conclusionsHumanized anti-CEA antibodies conjugated to near-infrared dyes provide specific labeling of gastric cancers in mouse models. Orthotopic models demonstrated bright and specific labeling with TBRs greater than ten times that of control. This tumor-specific fluorescent antibody is a promising potential clinical tool for improving visualization of gastric cancer margins at time of surgical resection.

Indexed as

Stomach NeoplasmsAnimalsAntibodies, MonoclonalCarcinoembryonic AntigenCell Line, TumorDisease Models, AnimalFluorescent DyesHumansImmunoglobulin GMiceMice, NudeAntibodies, MonoclonalCarcinoembryonic AntigenFluorescent DyesImmunoglobulin GCEAFluorescenceFluorescent antibodyGastric cancerOrthotopic mouse modelTumor labeling

Identifiers

PMID37839102
PMCPMC11060874
OpenAlexW4387647001

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.